0
Comments, Opinions, and Brief Case Reports |

Prasugrel as a Potential Cancer Promoter: Review of the Unpublished Data

James S. Floyd, MD; Victor L. Serebruany, MD, PhD
Arch Intern Med. 2010;170(12):1078-1080. doi:10.1001/archinternmed.2010.154.
Text Size: A A A
Published online

Extract

On July 10, 2009, the US Food and Drug Administration (FDA) approved prasugrel for use in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention based on the results of the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38 (TRITON–TIMI 38), a multicenter randomized clinical trial of 13 608 patients that showed a 19% relative risk reduction in the composite end point of nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death with prasugrel compared with clopidogrel.1,2 Like other thienopyridines, prasugrel irreversibly inhibits platelet activation and aggregation through a P2Y12-receptor dependent mechanism. However, based on conventional aggregation studies, the approved daily dose of prasugrel (10 mg) appears to be 2.5 to 2.7 times more potent than the standard 75-mg daily dose of clopidogrel, and a 50% increase in life-threatening hemorrhage and a 4-fold increase in fatal hemorrhage were observed in TRITON-TIMI 38.2,3

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
/>
First page PDF preview

Figures

Place holder to copy figure label and caption
Figure.

Kaplan-Meier plots. A, Kaplan-Meier plots for new solid cancers, excluding nonmelanoma skin cancers and brain tumors (P = .02 by log rank test). B, Kaplan-Meier plots for new and worse solid cancers, excluding nonmelanoma skin cancers and brain tumors (P = .001 by log rank test).

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 15

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles
Jobs
JAMAevidence.com

The Rational Clinical Examination
Make the Diagnosis: Cancer, Family History

The Rational Clinical Examination
Original Article: Does This Patient Have a Family History of Cancer?

brightcove.createExperiences();